EL Bioscience , a bio startup invested in by GenAxis, has been selected for the Tech Incubator Program for Startups (TIPS), a technology startup support program hosted by the Ministry of SMEs and Startups. This selection was achieved through GenAxis' initial investment and recommendation.
Through the TIPS R&D project, Elbioscience plans to conduct research and development and technology verification on a liquid crystal-based long-acting injectable formulation platform technology in a phased manner. The project aims to conduct R&D from a formulation technology perspective in the field of long-acting injectables and establish a technological foundation for future commercialization and regulatory approvals.
The technology currently under development by EL Bioscience is a sustained-release injectable formulation platform that utilizes the formulation's properties, which form a liquid crystal structure after administration, to control drug release. This technology is being researched to address the formulation and operational limitations of existing solid suspension or implantable sustained-release injectables, including the complexity of the manufacturing process, difficulties in managing initial release, and the burden of aseptic processing. This project will focus on the formulation's structural characteristics, verifying its applicability, manufacturing process suitability, release characteristics, and stability.
Through the TIPS project, Elbioscience plans to sequentially pursue the following: advancing liquid crystal-based sustained-release injectable formulation technology, researching platform technology standardization, securing basic data through non-clinical evaluations, and revising technical documentation with future regulatory approvals in mind. Rather than definitively determining specific efficacy or clinical outcomes, the research will focus on ensuring versatility, reproducibility, and process stability as a formulation technology applicable to a variety of active ingredients.
In the global biopharmaceutical market, sustained-release injectable technology continues to attract attention for its ability to improve patient convenience and shorten dosing cycles. However, the technology is considered to have high technological barriers to entry in terms of formulation stability, mass production processes, and regulatory compliance, making systematic R&D and validation in the early stages crucial. Through this TIPS project, LBioscience will conduct phased R&D and validation based on domestic formulation technology, and will also explore joint development and technology transfer opportunities in the mid- to long-term.
GenAxis stated that EL Bioscience is pursuing a formulation technology-centered approach in the field of sustained-release injectables, and that it expects this TIPS project to gradually verify its technological perfection and commercialization potential. The company added that it plans to continue supporting the entire R&D process, including commercialization strategies, regulatory review, and identifying follow-up collaboration opportunities.
Elbioscience is a bio venture company conducting research and development with its core competency being the formulation technology of long-acting injectable drugs. Based on future research results, the company plans to gradually explore possibilities for collaboration with domestic and foreign pharmaceutical companies and related companies and establish a mid- to long-term growth strategy.
You must be logged in to post a comment.